Eastern European countries continue to look beyond the Western firms supplying vaccines as the pandemic rages in this part of the world. Most recently, CanSino…
This week, the China National Medical Products Administration (NMPA) granted conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the “Ad5-nCoV”, trade name:…
CanSino Biologics, one of China’s leading vaccine makers, inked a deal with Pakistan’s government to sell the Ad5-nCoV vaccine candidate to that nation selling 10,600,000…
Mexico was active recently in the investigational vaccine market, securing two deals with two different companies for a total of 151 million doses of experimental…
Pakistan, the fifth most populous nation in the world, recently geared up to support a Phase 3 COVID-19 vaccine clinical trial sponsored by a Chinese…
The World Health Organization (WHO) now purportedly considers China as its strategic COVID-19 vaccine supplier as the world’s most populous nation—representing the second largest GDP…
Indonesia is preparing to support the commercialization of CanSino Biologics’ Ad5-nCoV vaccine candidate as Solution Biologics Sdn Bhd (SOLBIO), a subsidiary of Solution Group Bhd,…
According to local reports out of Russia (Moscow Times), the Phase 3 clinical trial investigating Cansino Biologics’ COVID-19 vaccine candidate, known as Ad5-nCoV, has been…
As seven vaccines worldwide have moved to the final stages of testing (e.g. Phase 3 clinical trials), four of them are in China. And recently…
Canada has finally made the call to terminate the CanSino Biologics Ad5-nCoV clinical trial, the nation’s first such study targeting a potential COVID-19 vaccine. After months…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
